Free Trial

Acelyrin (SLRN) Stock Price, News & Analysis

+0.43 (+7.54%)
(As of 04:24 PM ET)
Today's Range
50-Day Range
52-Week Range
1.22 million shs
Average Volume
1.08 million shs
Market Capitalization
$607.05 million
P/E Ratio
Dividend Yield
Price Target

Acelyrin MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
116.6% Upside
$12.80 Price Target
Short Interest
11.28% of Float Sold Short
Dividend Strength
News Sentiment
1.37mentions of Acelyrin in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.33) to ($4.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

Medical Sector

582nd out of 912 stocks

Pharmaceutical Preparations Industry

280th out of 434 stocks

SLRN stock logo

About Acelyrin Stock (NASDAQ:SLRN)

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

SLRN Stock Price History

SLRN Stock News Headlines

Acelyrin (NASDAQ:SLRN) Upgraded at Wells Fargo & Company
Does this make you sick?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
Acelyrin, Inc. (SLRN)
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
Acelyrin Founder Steps Down as CEO
Does this make you sick?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
ACELYRIN, INC. Announces Leadership Transition
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
See More Headlines
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$6.74 per share


Free Float
Market Cap
$567.44 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Ms. Melanie Gloria B.S.N. (Age 46)
    Chief Operating Officer
    Comp: $667.52k
  • Ms. Mina Kim (Age 50)
    CEO & Director
  • Mr. Gilbert M. Labrucherie J.D. (Age 52)
    CFO & Chief Business Officer
  • Mr. Tyler Marciniak
    Head of Investor Relations & Communications
  • Ms. Sanam Pangali J.D.
    Chief Legal Officer & Head of People
  • Dr. Paul M. Peloso M.D. (Age 66)
    M.Sc., Chief Medical Officer
  • Ms. Suzy Buckhalter CPA
    Senior Director of Finance & Accounting
  • Mr. Kenneth A. Lock (Age 50)
    Chief Commercial Officer
  • Dr. Shephard Mpofu M.D.
    Chief Medical Officer
  • Ms. Patricia A. Turney (Age 57)
    Chief Technical Operations Officer

SLRN Stock Analysis - Frequently Asked Questions

How have SLRN shares performed this year?

Acelyrin's stock was trading at $7.46 at the start of the year. Since then, SLRN stock has decreased by 20.8% and is now trading at $5.91.
View the best growth stocks for 2024 here

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.57.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering (IPO) on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

Who are Acelyrin's major shareholders?

Top institutional investors of Acelyrin include SG Americas Securities LLC (0.01%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg and Ronald Oyston.
View institutional ownership trends

How do I buy shares of Acelyrin?

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLRN) was last updated on 7/15/2024 by Staff

From Our Partners